These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

611 related articles for article (PubMed ID: 27164716)

  • 1. Practice guideline update summary: Botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache: Report of the Guideline Development Subcommittee of the American Academy of Neurology.
    Simpson DM; Hallett M; Ashman EJ; Comella CL; Green MW; Gronseth GS; Armstrong MJ; Gloss D; Potrebic S; Jankovic J; Karp BP; Naumann M; So YT; Yablon SA
    Neurology; 2016 May; 86(19):1818-26. PubMed ID: 27164716
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The cost-effectiveness of abobotulinumtoxinA (Dysport) and onabotulinumtoxinA (Botox) for managing spasticity of the upper and lower limbs, and cervical dystonia.
    Danchenko N; Johnston KM; Whalen J
    J Med Econ; 2022; 25(1):919-929. PubMed ID: 35730362
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evidence on botulinum toxin in selected disorders.
    Zakin E; Simpson D
    Toxicon; 2018 Jun; 147():134-140. PubMed ID: 29408357
    [TBL] [Abstract][Full Text] [Related]  

  • 4. AAN Updates Guidelines on the Uses of Botulinum Neurotoxin.
    Wilkes J
    Am Fam Physician; 2017 Feb; 95(3):198-199. PubMed ID: 28145664
    [No Abstract]   [Full Text] [Related]  

  • 5. Evidence-based review and assessment of botulinum neurotoxin for the treatment of movement disorders.
    Hallett M; Albanese A; Dressler D; Segal KR; Simpson DM; Truong D; Jankovic J
    Toxicon; 2013 Jun; 67():94-114. PubMed ID: 23380701
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evidence-based review and assessment of botulinum neurotoxin for the treatment of adult spasticity in the upper motor neuron syndrome.
    Esquenazi A; Albanese A; Chancellor MB; Elovic E; Segal KR; Simpson DM; Smith CP; Ward AB
    Toxicon; 2013 Jun; 67():115-28. PubMed ID: 23220492
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Significant Long-Lasting Improvement after Switch to Incobotulinum Toxin in Cervical Dystonia Patients with Secondary Treatment Failure.
    Hefter H; Ürer B; Brauns R; Rosenthal D; Meuth SG; Lee JI; Albrecht P; Samadzadeh S
    Toxins (Basel); 2022 Jan; 14(1):. PubMed ID: 35051021
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dysport (botulinum toxin type A) in routine therapeutic usage: a telephone needs assessment survey of European physicians to evaluate current awareness and adherence to product labeling changes.
    Hubble J; Schwab J; Hubert C; Abbott CC
    Clin Neuropharmacol; 2013; 36(4):122-7. PubMed ID: 23783005
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Concurrent onabotulinumtoxinA treatment of cervical dystonia and concomitant migraine.
    Winner PK; Sadowsky CH; Martinez WC; Zuniga JA; Poulette A
    Headache; 2012 Sep; 52(8):1219-25. PubMed ID: 22607530
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical and pharmacological properties of incobotulinumtoxinA and its use in neurological disorders.
    Jost WH; Benecke R; Hauschke D; Jankovic J; Kaňovský P; Roggenkämper P; Simpson DM; Comella CL
    Drug Des Devel Ther; 2015; 9():1913-26. PubMed ID: 25897202
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative efficacy, safety, and cost-effectiveness of abobotulinumtoxinA and onabotulinumtoxinA in children with upper limb spasticity: a systematic literature review, indirect treatment comparison, and economic evaluation.
    Danchenko N; Johnston KM; Haeussler K; Whalen J
    J Med Econ; 2021; 24(1):949-961. PubMed ID: 34340647
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical guidelines: No more mistaken identities for botulinum neurotoxins.
    Albanese A
    Nat Rev Neurol; 2016 Jul; 12(7):373-4. PubMed ID: 27313106
    [No Abstract]   [Full Text] [Related]  

  • 13. Botulinum toxin type-A preparations are not the same medications - clinical studies (Part 2).
    Sławek J; Bogucki A; Bonikowski M; Car H; Dec-Ćwiek M; Drużdż A; Koziorowski D; Sarzyńska-Długosz I; Rudzińska M
    Neurol Neurochir Pol; 2021; 55(2):141-157. PubMed ID: 33797748
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-World Dosing of OnabotulinumtoxinA and IncobotulinumtoxinA for Cervical Dystonia and Blepharospasm: Results from TRUDOSE and TRUDOSE II.
    Kent R; Robertson A; Quiñones Aguilar S; Tzoulis C; Maltman J
    Toxins (Basel); 2021 Jul; 13(7):. PubMed ID: 34357959
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A guide to dosing in the treatment of cervical dystonia and blepharospasm with Xeomin®: a new botulinum neurotoxin A.
    Pagan FL; Harrison A
    Parkinsonism Relat Disord; 2012 Jun; 18(5):441-5. PubMed ID: 22405829
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Practice parameter: pharmacologic treatment of spasticity in children and adolescents with cerebral palsy (an evidence-based review): report of the quality standards subcommittee of the american academy of neurology and the practice committee of the child neurology society.
    Whelan MA; Delgado MR
    Neurology; 2010 Aug; 75(7):669. PubMed ID: 20713958
    [No Abstract]   [Full Text] [Related]  

  • 17. Transient Improvement after Switch to Low Doses of RimabotulinumtoxinB in Patients Resistant to AbobotulinumtoxinA.
    Hefter H; Samadzadeh S; Moll M
    Toxins (Basel); 2020 Oct; 12(11):. PubMed ID: 33121133
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IncobotulinumtoxinA (Xeomin®) injected for blepharospasm or cervical dystonia according to patient needs is well tolerated.
    Evidente VG; Truong D; Jankovic J; Comella CL; Grafe S; Hanschmann A
    J Neurol Sci; 2014 Nov; 346(1-2):116-20. PubMed ID: 25186131
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The use of botulinum toxin type A in the management of adult-onset focal spasticity: a survey of Australian allied health professionals.
    Williams G; Olver J; de Graaff S; Singer BJ
    Aust Occup Ther J; 2012 Aug; 59(4):257-64. PubMed ID: 22934898
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Frequency and risk factors of antibody-induced secondary failure of botulinum neurotoxin therapy.
    Walter U; Mühlenhoff C; Benecke R; Dressler D; Mix E; Alt J; Wittstock M; Dudesek A; Storch A; Kamm C
    Neurology; 2020 May; 94(20):e2109-e2120. PubMed ID: 32332130
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.